A groundbreaking study published in the journal Cell has unveiled a pivotal role for the immune system in suppressing the spread of breast cancer (1). The research highlights how lung-resident alveolar macrophages (AMs) act as an innate immune barrier, inducing dormancy in disseminated breast cancer cells (DCCs) and preventing them from forming deadly metastases. This breakthrough offers promising new avenues for preventing and treating metastatic breast cancer.

 

Fig.: Unlocking the mysteries of cancer dormancy – Alveolar macrophages as cancer cell dormancy enforcers

Unlocking the Mysteries of Cancer Dormancy

Metastasis, the spread of cancer to distant organs, is responsible for the majority of cancer-related deaths. Disseminated breast cancer cells (DCCs) are cancer cells that have detached from the primary breast tumor and traveled to distant sites in the body through the bloodstream or lymphatic system. These cells are often found in secondary organs such as the lungs, liver, bones, or brain, where they may remain dormant or progress into metastatic tumors. Previous studies have identified various factors contributing to cancer cell dormancy and metastasis, including specific niche signals in secondary organs. For instance, transforming growth factor (TGF)-β2 and bone morphogenetic protein 4 (BMP4) were previously shown to induce dormancy in disseminated cancer cells in the lung. However, the cellular source and mechanisms of these dormancy-inducing signals remained unclear. This study builds upon and significantly extends this knowledge by identifying alveolar macrophages as key players in this process.

Alveolar macrophages, specialized immune cells residing in the tiny air sacs (alveoli) of the lungs, are primarily known for their roles in maintaining lung health by clearing debris and regulating inflammation. This study, led by Dr. Julio A. Aguirre-Ghiso of Albert Einstein College of Medicine, reveals their previously unknown function as guardians against metastatic outgrowth.

The researchers employed a multi-faceted approach to prove their hypothesis:

  •  Single-cell RNA sequencing (scRNA-seq): They profiled lung macrophages from early and late-stage HER2+ breast cancer mouse models, revealing that homeostatic AMs remain the dominant macrophage population throughout cancer progression.
  • High-resolution imaging: Using immunofluorescence, precision-cut lung slices, and intravital microscopy, they demonstrated frequent and persistent interactions between AMs and DCCs in the lung alveolar space.
  • In vitro co-culture experiments: They showed that AMs induce a mesenchymal-like, growth-arrested phenotype in early lesion (EL) breast cancer cells, but not in more advanced primary tumor (PT) cells.
  • Transcriptomic analysis: RNA sequencing revealed distinct transcriptional changes in both cancer cells and AMs following their interaction, supporting the observed phenotypic changes.
  • In vivo depletion experiments: Critically, they demonstrated that depleting AMs using clodronate liposomes led to reactivation of dormant lung DCCs and increased metastatic burden.

The Discovery: Alveolar Macrophages as Dormancy Enforcers

The study found that AMs interact with DCCs in the lungs, inducing dormancy through a signaling pathway involving TGF-β2 and its receptor, TGF-βRIII, on cancer cells. Key findings include:

  • AM-DCC Interaction: AMs form frequent and prolonged interactions with DCCs, signaling through TGF-β2 to maintain cancer cell dormancy.
  • Dormancy Suppression Mechanism: Depleting AMs or inactivating TGF-βRIII in DCCs reactivates dormant cells, leading to aggressive metastatic growth.
  • Escape from Dormancy: Advanced breast cancer cells evade this immune barrier by downregulating TGF-βRIII, overcoming AM-mediated dormancy induction.

Why This Matters

Dr. Aguirre-Ghiso explains,

                                      “We’ve uncovered an innate immune mechanism that keeps cancer cells dormant, providing a                                                 natural defense against metastasis. This discovery could fundamentally change how we approach metastatic breast cancer prevention and treatment.”

The implications are profound:

  • Therapeutic Potential: Restoring or enhancing TGF-β2-TGF-βRIII signaling could reactivate dormancy pathways in advanced-stage cancer cells.
  • Biomarker Development: Measuring TGF-βRIII levels could help assess a patient’s metastatic risk.
  • Personalized Treatment: Understanding individual variations in AM function and DCC characteristics could inform tailored therapeutic strategies.

Revolutionizing Breast Cancer Metastasis Treatment

This research paves the way for new therapeutic strategies, including:

  • Restoration of Dormancy: Drugs targeting the TGF-β2-TGF-βRIII pathway could prevent reactivation of dormant cancer cells.
  • Immune Niche Engineering: Enhancing AM function may sustain dormancy and prevent metastatic growth.
  • Prognostic Tools: TGF-βRIII expression levels could serve as biomarkers for assessing metastatic potential.
  • Immunotherapy Innovations: Developing therapies that mimic AM dormancy-inducing effects offer a novel approach to metastasis prevention.

A Paradigm Shift in Understanding Metastasis

While earlier studies highlighted the role of TGF-β in cancer dormancy, this study is the first to identify AMs as a critical source of TGF-β2 and as key regulators of dormancy. The discovery fills a significant gap in metastasis research, explaining why some DCCs remain dormant for decades while others form aggressive metastases.
While earlier studies highlighted the role of TGF-β in cancer dormancy, this study is the first to identify AMs as a critical source of TGF-β2 and as key regulators of DCC dormancy in the lung (2). The discovery fills a significant gap in metastasis research, explaining why some DCCs remain dormant for decades while others form aggressive metastases.

Looking Forward

The findings highlight a promising new direction in cancer research. Dr. Aguirre-Ghiso, states,

                    “This work provides a new framework for understanding how the immune system naturally suppresses                                       metastasis. It opens the door to transformative therapies harnessing the body’s defenses against cancer spread.”

While further research is needed to translate these findings into clinical practice, the implications are clear: harnessing the natural defense mechanisms of alveolar macrophages could revolutionize breast cancer treatment, offering hope to millions of patients worldwide.

References

  1. Dalla, E., et al. (2024) Lung-resident alveolar macrophages regulate the timing of breast cancer metastasis. Cell, 187, 6631–6648. DOI: 10.1016/j.cell.2024.09.016
  2. Nobre, R.R., et al (2021) Bone marrow NG2+/Nestin+ mesenchymal stem cells drive DTC dormancy via TGFβ2. Nat Cancer. 2:327–339. doi: 10.1038/s43018-021-00179-8

Drug Discovery & Development Assays Offered by Marin Biologic Laboratories